Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 269-665-4 | CAS number: 68308-74-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 March 2013 to 13 November 2013
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Reliable, GLP and OECD Test Guideline No 422 compliant study providing results from a proprietary screening study.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Amides, tall-oil fatty, N,N-di-Me
- EC Number:
- 269-665-4
- EC Name:
- Amides, tall-oil fatty, N,N-di-Me
- Cas Number:
- 68308-74-7
- Molecular formula:
- not applicable for UVCB
- IUPAC Name:
- Amides, tall-oil fatty, N,N-di-Me
- Reference substance name:
- DMATO
- IUPAC Name:
- DMATO
- Reference substance name:
- Dimethylamide van Talolie
- IUPAC Name:
- Dimethylamide van Talolie
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): DMATO
- Analytical purity: 100%
- Lot/batch No.: 12J46399
- Expiration date of the lot/batch: October 2015
- Storage condition of test material: At room temperature (20 ± 5°C) and protected from light
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:male and female Wistar Hannover RccHan:WIST rats, obtained from Harlan Laboratories Models, S.L
- Age at study initiation: 11-12 weeks
- Weight at study initiation: Males: 346-383g; Females: 190-225g
- Fasting period before study: not applicable
- Housing:in standard laboraotory caging, group housd prior to mating; pair housed one male and one femal during mating phase and hosused individually subsequently
- Diet (e.g. ad libitum): Pelleted Harlan Teklad 2014C or 2018C rat/mouse maintenance diet provided ad libitum
- Water (e.g. ad libitum): Bottled tap water available ad libitum
- Acclimation period:The rats were acclimatised for at least 5 days prior to the start of the study.
Experimental dates 25 March 2013 to 13 November 2013
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- The amount of test material and administration volume was determined for each animal based on the most recent body weight. The dose volume was 4 mL/kg bw. No correction for purity was applied to the administered dose.
Dose levels were selected based on a dose range-finding study (Study S41514). Dose levels of 0, 50, 300 and 1000 mg/kg bw/day were chosen for the main study.
Oral gavage administration daily for two weeks prior to mating; males were dosed daily for at least 48 days after mating up to and including the day before sacrifice; the females were dosed up to and including the day before sacrifice (day 4 postpartum). - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Aliquots were taken from each of the dose formulations and analysed for concentration and homogeneity using GC-FID. Analyses were completed twice during treatment in the first week of treatment and during the post-pairing period. Homogeneity analyses were completed during the first week of treatment.
The results obtained showed the concentrations in the formulations ranged from 86.0% to 117.1% (within the accepted range of 80-120%) and the CV for homogeneity did not exceed 6%. - Duration of treatment / exposure:
- Males: two weeks prior to mating and at least up to and including the day before sacrifice (at least a total of 28 days).
Females: two weeks prior to mating and at least up to and including the day before sacrifice (day 4 postpartum). - Frequency of treatment:
- Daily.
Day 1: First treatment
Day 1 to 15: - pre-pairing treatment (checks for morbidity, bodyweight, food consumption and clinical signs)
Day 15: mating (checks for morbidity, bodyweight, clinical signs and evidence of mating - vaginal smears)
Day 16 - Day 0 of pregnancy
Day 16 to 37 - gestation (checks for morbidity, bodyweight, food consumption and clinical signs)
Day 37: Delivery
Day 38: Lactation F0 females (checks for nursing, morbidity, bodyweight, food consumption and clinical signs)
F1 litter size , sex, bodyweight, clinical signs and a behaviour test
F0 males (checks for morbidity, bodyweight and clinical signs)
Day 41: End of treatment (F0 females: day 4 postpartum (checks for grip strength, motor activity, sensory reactivity to stimuli) and F1 necropsy; F0 males (grip strength, motor activity, sensory reactivity to stimuli).
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 50, 300, 1000 mg/kg bw/d
Basis:
other: nominal
- No. of animals per sex per dose:
- 10 rats/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose levels were chosen based on a 14-day range finding study
- Positive control:
- Not required ofr this study type
Examinations
- Observations and examinations performed and frequency:
- The animals were observed for morbidity/mortality at least twice daily. Cage-side clinical observations were made at least once daily.
Detailed clinical observations were performed on all test and control group animals before the first exposure, once weekly thereafter and one day before sacrifice. These observations were performed outside the home cage in a standard arena, at least one hours after dosing.
Functional performance tests (grip strength; fore and hind limbs and motor activity) were conducted in five randomly selected males per group once during the final week of treatment and at least one hour after dosing. Five randomly selected females per group were similarly evaluated on day 4 postpartum. Sensory reactivity to different stimuli (e.g. auditory, visual and proprioceptive) were evaluated in the same animals subject to functional performance tests.
Food consumption was determined once weekly in males during the pre-pairing period and two weeks of postpairing. Food consumption in females was determined once weekly during the pre-pairing period and days 0-7, 7-14, 14-21 post coitum and days 1-4 post partum. Body weights were recorded for males twice weekly during the pre-pairing and pairing period and daily during the postpairing period. Female body weights were recorded twice weekly during the pre-pairing and pairing period and daily until day 4-5 post partum. Blood was collected from 5 males on at least day 43 of treatment (day of sacrifice) and from 5 females on approximately day 5 post partum (day of sacrifice) for clinical laboratory investigations.
From day 21 postcoitum, the females were examined at least twice daily for signs of parturition. Gestation length was recorded.
For the F0 generation twice daily checks were made for morbidity and mortality and once daily cage-side checks of clinical signs. A detailed behavioural assessment was completed for the test and control animals at weekly intervals. A functional performance test for grip strength and motor activity, sensory reactivity assesssments for auditory, visual and proprioceptive stimuli were evaluated. Food consumption was measured for the males at weekly intervals during the pre-pairing period and during two weeks of the post-mating phase and at weekly intervals through the study for the females.
water consumption was recorded for males during day 7-15 post-pairing and for females on days 6-14 post coitum.
Bodyweights were recorded for at weekly intervals pre-pairing and daily thereafter.
Vaginal smears were collected from all females and examined for oestrous cycling during the mating phase. Smears were discontinued when sperm were found.
The females were checked from day 21 postcoitum for signs of parturition and gestation length was recorded. The females that gave birth were observed to determine if they nursed their young. - Sacrifice and pathology:
- Females were sacrificed on approximately day 5 post partum and necropsied. Males were sacrificed on at least day 43 of the study. All sacrificed animals were examined macropscopically. Tissues were collected for histopathological processing and determination or organ weights.
Any rat sacrificed or found dead during the study was examined macroscopically. Gross macroscopic examination was performed of all internal organs with emphasis on the uterus, count of corpora lutea and implantation sites. If no implantation sites were found then the uterus was placed in an aqueous solution of ammonium sulphide to highlight implantation sites. F0 females were terminated on day 5 post partum. The mated females that did not give birth or show any signs of pregnancy (five individuals numbers 58, 62, 65, 71 and 78) were terminated 26 days post coitum. - Other examinations:
- A qualitative staging of spermatogenesis and histopathology evaluation of interstitial cells of all males from the control and high dose groups was performed.
- Statistics:
- Dunnett's test, Fisher's Exact test and Steel's test were variously used on study parameters
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Salivation was recorded in males and females from control and at 50, 300 and 1000 mg/kg bw/day, with greater incidence at 1000 mg/kg bw/day.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Salivation was recorded in males and females from control and at 50, 300 and 1000 mg/kg bw/day, with greater incidence at 1000 mg/kg bw/day.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Lower body-weight gain was recorded in males at 300 and 1000 mg/kg bw/day and females at 1000 mg/kg bw/day during the premating period;
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Higher water consumption was recorded in both sexes at 1000 mg/kg bw/day.
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- An increase in reticulocyte values and white blood cells was observed in males at 1000 mg/kg bw/day
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- An increase in cholesterol and triglyceride levels was recorded at 300 and 1000 mg/kg bw/day in males and at 1000 mg/kg bw/day in females. Moreover, increases in alkaline phosphatase and alanine aminotransferase were recorded at 1000 mg/kg bw/day
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- Lower locomotor activity was recorded in both sexes at 300 and 1000 mg/kg bw/day.
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- An increase in liver weight was recorded in males at 300 and 1000 mg/kg bw/day and females at 1000 mg/kg bw/day. Moreover, higher kidney weight was recorded in males at 1000 mg/kg bw/day.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Reddish discoloration of the mesenteric lymph node was observed in 0/10, 0/10, 0/10 and 5/10 males and in 0/10, 0/10, 1/10 and 2/10 females at 0, 50, 300 and 1000 mg/kg bw/day, respectively.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- various findings in both sexes at 1000 mg/kg bw/day. Hepatocellular hypertrophy was seen in males at 300 mg/kg bw/d
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- MORTALITY
No deaths occurred.
CLINICAL SIGNS
Salivation was recorded in males and females from control and at 50, 300 and 1000 mg/kg bw/day, with greater incidence at 1000 mg/kg bw/day.
BODY WEIGHT AND WEIGHT GAIN
Lower bodyweight gain was recorded in males at 300 and 1000 mg/kg bw/day and females at 1000 mg/kg bw/day during the premating period; afterwards there was a recovery in bodyweight. No test-item related differences from the control group were recorded at 50 mg/kg bw/day.
FOOD CONSUMPTION
There were no effects of treatment
WATER CONSUMPTION
Higher water consumption was recorded in both sexes at 1000 mg/kg bw/day. No significant differences were recorded at 50 and 300 mg/kg bw/day.
HAEMATOLOGY
In males at 300 and 1000 mg/kg bw/day, reticulocyte values, median fluorescence reticulocyte ratio (MFR) and low fluorescence reticulocyte ratio (LFR) increased with respect to the control group. These differences were statistically significant at 1000 mg/kg bw/day and, only in reticulocyte count, at 300 mg/kg bw/day. In addition, higher white blood cell values were recorded at 1000 mg/kg bw/day. No differences with the control groups were recorded at 50 mg/kg bw/day or in females of any group.
CLINICAL CHEMISTRY
An increase in cholesterol and triglyceride levels was recorded at 300 and 1000 mg/kg bw/day in males and at 1000 mg/kg bw/day in females. Moreover, increases in alkaline phosphatase and alanine aminotransferase were recorded at 1000 mg/kg bw/day in males and females. No relevant differences were observed at 50 mg/kg bw/day.
NEUROBEHAVIOUR
Lower locomotor activity was recorded in both sexes at 300 and 1000 mg/kg bw/d and in males at 50 mg/kg bw/day. No relevant differences from the control group were recorded in the grip strength test in either sex. All animals showed a normal behavior and appearance. All animals responded positively to the different reflexes such as palpebral, righting and iridial reflexes and pain, auditory startle and handling response (push-off).
ORGAN WEIGHTS
Higher liver weights were recorded at 300 and 1000 mg/kg bw/day in males and at 1000 mg/kg bw/day in females. These differences were statistically significant in relative to body and brain weight in both sexes at 1000 mg/kg bw/day. In addition, a significantly higher kidney weight was recorded at 1000 mg/kg bw/day in males. A higher thymus weight at 300 and 1000 mg/kg bw/day and adrenal weight at 1000 mg/kg bw/day was observed in females. These differences were not statistically significant. No relevant differences from the control group were recorded at 50 mg/kg bw/day.
Concerning reproductive organs, lower weight of the testes was recorded in males no. 18 at 50 mg/kg bw/day, 29 at 300 mg/kg bw/day and 33 at 1000 mg/kg bw/day. No differences in weight were recorded in female reproductive organs.
GROSS PATHOLOGY
No treatment-related alterations were recorded in the offspring at necropsy. Reddish discoloration of the mesenteric lymph node was observed in 0/10, 0/10, 0/10 and 5/10 males and in 0/10, 0/10, 1/10 and 2/10 females at 0, 50, 300 and 1000 mg/kg bw/day, respectively. All other lesions recorded were considered to be within the normal range of background alterations observed in rats of this strain and age and under the experimental conditions used in this study.
HISTOPATHOLOGY
At 1000 mg/kg bw/day, slight hepatocellular hypertrophy in the liver was recorded in males and females, the enlarged hepatocytes displaying a “ground glass appearance”. In the thyroid minimal to moderate follicular cell hypertrophy was observed in males and females; the changes were characteried by the presence of irregularly shaped follicles lined by columnar cells and containing a small amount of pale-staining colloid. In the pituitary, minimal cell hypertrophy was recorded in the pars distalis of 1/10 males; the finding was characterized by an increased number of scattered enlarged pale eosinophilic cells. Moreover, a decrease in lymphocytes was observed with higher incidence in the mesenteric lymph node of males and females and in the thymus of males. In kidneys, hyaline droplets within the proximal tubule lining cells were recorded with higher incidence and severity in males compared to the control group. Non-pregnant rat no. 71 had diffuse vacuolation of the ovaries (involving interstitial, luteal and follicular cells) and vacuolation of the epithelial cells lining the oviducts. In this animal, vacuolation was also present in the enlarged adrenals observed at necropsy. In the other females, the ovaries, oviducts, uterus, cervix and vagina were unremarkable, in particular the ovarian follicles and corpora lutea. At 300 mg/kg bw/day, minimal hepatocellular hypertrophy in the liver was recorded in males., but not in females. At 50 mg/kg bw/day, No hepatocellular hypertrophy in the liver was recorded in males or in females. All other findings recorded were within the range of normal background lesions which may be
recorded in animals of this strain and age.
OTHER FINDINGS
Sperm Stage Evaluation revealed severe diffuse bilateral tubular degeneration and was associated with marked oligospermia or aspermia in the epididymides was recorded in males that showed small testes and/or epididymides. No remarkable findings were recorded in the remaining males from highand control groups.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: The NOAEL for males of 50 mg/kg bw/day is based on increased liver weight, hepatocyte hypertrophy and a significant increase in serum cholesterol at 300 mg/kg bw/d.
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: The NOAEL for females of 300 mg/kg bw/d is based on reduced weight gain, increased liver weight, hepatocyte hypertrophy and a significant increase in serum cholesterol at the highest dose level of 1000 mg/kg bw/d.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Summary of in-life findings
Parameter |
M |
F |
||||||
0 |
50 |
300 |
1000 |
0 |
50 |
300 |
1000 |
|
Locomotor activity (counts) |
1563 |
1097* |
764** |
647** |
823 |
767 |
677 |
597 |
Water consumption (g/day) |
26.8 |
29.9 |
30.5 |
44.8 |
27.3 |
35.6 |
32.9 |
45.6 |
Pre-mating weight (g) |
410.4 |
410.2 |
397.5 |
384.2** |
226.9 |
225.1 |
222.7 |
226.6 |
Terminal weight (g) |
454.3 |
457.3 |
437.2 |
422.4** |
|
|
|
|
Reticulocytes (%) |
1.4 |
1.7 |
3.4* |
2.0* |
5.0 |
7.7 |
5.3 |
5.9 |
Reticulocytes (G/L) |
132.2 |
157.5 |
283.6 |
184.3 |
360.6 |
523.4 |
376.3 |
441.3 |
LFR |
0.776 |
0.726 |
0.654 |
0.698* |
0.478 |
0.478 |
0.505 |
0.543 |
MFR |
0.213 |
0.258 |
0.302 |
0.282* |
0.417 |
0.420 |
0.394 |
0.392 |
HFR |
0.011 |
0.016 |
0.044* |
0.019 |
0.105 |
0.102 |
0.101 |
0.065 |
WBC (G/L) |
6.6 |
7.6 |
7.3 |
8.8** |
5.9 |
6.3 |
5.7 |
5.6 |
Lymphocytes (G/L) |
5.1 |
6.1 |
5.3 |
6.9* |
3.7 |
3.7 |
3.3 |
3.5 |
Cholesterol (mM) |
2.01 |
1.80 |
2.65* |
3.16** |
1.77 |
2.56 |
2.43 |
2.89* |
ALT (U/L) |
33.3 |
30.8 |
33.3 |
45.4* |
35.6 |
39.7 |
44.4 |
45.0 |
ALP (U/L) |
61.8 |
49.5 |
49.8 |
90.8* |
36.1 |
34.4 |
36.8 |
47.5 |
P (mM) |
1.69 |
1.71 |
1.88 |
1.95* |
2.23 |
2.35 |
2.16 |
2.26 |
Na (mM) |
144.3 |
144.2 |
145.6 |
146.7** |
138.9 |
139.9 |
139.0 |
139.1 |
Cl (mM) |
99.8 |
99.1 |
100.1 |
103.1** |
100.1 |
100.9 |
100.5 |
100.5 |
Protein (g/L) |
67 |
68 |
68 |
63* |
62 |
65 |
67 |
65 |
Globulin (g/L) |
17 |
20 |
20 |
22* |
23 |
23 |
22 |
19 |
A:G ratio |
2.59 |
2.31 |
2.28 |
1.94* |
1.96 |
1.92 |
2.11 |
2.29 |
*significantly different to controls (p<0.05); **p<0.01
Summary of organ weight effects
Organ |
M |
F |
||||||
0 |
50 |
300 |
1000 |
0 |
50 |
300 |
1000 |
|
Liver weight (g) |
10.38 |
10.80 |
11.35 |
14.18** |
8.42 |
8.62 |
8.66 |
10.82** |
Liver weight (%) |
2.35 |
2.45 |
2.73** |
3.55** |
3.44 |
3.48 |
3.45 |
4.41** |
Liver weight (% brain) |
491.4 |
522.3 |
540.1 |
676.3** |
453.2 |
468.6 |
466.5 |
583.2** |
Thymus weight (g) |
0.361 |
0.400 |
0.301 |
0.288 |
0.190 |
0.195 |
0.237 |
0.234 |
Thymus weight (%) |
0.082 |
0.091 |
0.072 |
0.072 |
0.076 |
0.079 |
0.094 |
0.096 |
Thymus weight (% brain) |
17.0 |
19.4 |
14.3 |
13.7 |
10.2 |
10.6 |
13.0 |
12.7 |
Kidney weight (g) |
2.31 |
2.41 |
2.40 |
2.56* |
1.52 |
1.50 |
1.56 |
1.63 |
Kidney weight (%) |
0.52 |
0.55 |
0.58* |
0.64** |
0.62 |
0.61 |
0.62 |
0.66 |
Kidney weight (% brain) |
109.0 |
116.3 |
114.2 |
121.9** |
82.0 |
81.6 |
84.5 |
87.7 |
Prostate weight (g) |
2.95 |
3.01 |
2.78 |
2.52* |
|
|
|
|
Prostate weight (%) |
0.67 |
0.68 |
0.67 |
0.63 |
|
|
|
|
Prostate weight (% brain) |
139.6 |
15.8 |
132.4 |
120.0 |
|
|
|
|
*significantly different to controls (p<0.05); **p<0.01
Summary of necropsy findings
Finding |
M |
F |
||||||
0 |
50 |
300 |
1000 |
0 |
50 |
300 |
1000 |
|
Mesenteric lymph node: discoloured |
- |
- |
- |
5 |
- |
- |
1 |
2 |
Mesenteric lymph node: erythrocytosis |
- |
- |
- |
5 |
- |
- |
1 |
2 |
Hepatocyte hypertrophy |
- |
- |
4 |
9 |
- |
- |
- |
5 |
Kidney hyaline deposition |
- |
- |
- |
5 |
- |
- |
- |
- |
Applicant's summary and conclusion
- Conclusions:
- F0 generation - Males
Based on the results obtained, the dose of 50 mg/kg bw/day can be considered the NOEL (No Observed Effect Level) for toxic effects, and 300 mg/kg bw/day, the LOAEL (Low Observed Adverse effect Level) based on an increase in hepatocellular hypertrophy in liver and hyaline droplets within tubular epithelium in kidneys at 300 and 1000 mg/kg bw/day.
The dose of 1000 mg/kg bw/day can be considered the NOAEL (No Observed Adverse Effect Level) for fertility and mating performance.
F0 generation - Females
Based on the results obtained, the dose of 300 mg/kg bw/day can be considered the NOAEL for toxic effects, and 1000 mg/kg bw/day, the LOAEL based on an increase in hepatocellular hypertrophy in liver at 1000 mg/kg bw/day. The dose of 50 mg/kg bw/day can be considered the NOEL and 300 mg/kg bw/day, the LOAEL for fertility and mating performance based on the lower implantation sites and corpora lutea recorded at 300 and 1000 mg/kg bw/day.
F1 generation
The dose of 1000 mg/kg bw/day can be considered the NOAEL. - Executive summary:
This study was performed to OECD Guideline 422 [Combined repeated Dose Toxicity Study with the Reproduction /Developmental Toxicity Screening Test] with the Submission Substance DMATO. Groups of RccHan:WIST rats were gavaged with DMATO (in corn oil) at dose levels of 0 (vehicle control), 50, 300 or 1000 mg/kg bw/d at a constant dose volume of 4 mL/kg bw/d. Animals were dosed for a two week pre-mating period, throughout mating, and during pregnancy and early lactation for females). The dosing period for males was at least 49 days.
Clinical signs, behavioural assessments, body weights and food and water consumption were monitored during the study. Females were also frequently examined on days 21 and 22 of pregnancy in order to check delivery. Haematology and clinical biochemistry were evaluated at termination on five selected males and females from each dose group. Pairing of animals within each dose group was undertaken on a 1:1 basis within each treatment group on Day 15 of the study, with females subsequently being allowed to litter and rear their offspring up to Day 4 of lactation. During the lactation phase, clinical observations were recorded daily for all surviving offspring, together with litter size and offspring weights; and surface righting reflex was assessed. Extensive functional observations were performed on five selected males from each dose group the day before sacrifice and for five selected parental females from each dose group on Day 4 post partum. Adult males were terminated at least on Day 49, adult females on Day 5 post partum and offspring on Day 4 post partum. All animals were subjected to a gross necropsy examination and selected tissues from five males and five females from groups 1 and 4 were evaluated histopathologically.
No mortality was recorded during the study period. Salivation was recorded in males and females in all groups, with a greater incidence at 1000 mg/kg bw/day. Lower locomotor activity was recorded in both sexes at 300 and 1000 mg/kg bw/day. No relevant differences from the control group were recorded in the grip strength test in either sex. Sensory reactivity assessment did not reveal any differences from the control group; all animals showed a normal behaviour and appearance.
Higher water consumption was recorded in both sexes at 1000 mg/kg bw/day; no differences were recorded at 50 and 300 mg/kg bw/day. No relevant differences from the control group were recorded in food consumption. Lower body-weight gain was recorded in males at 300 and 1000 mg/kg bw/day and females at 1000 mg/kg bw/day during the pre-mating period; afterwards there was a recovery in bodyweight. No test-item related differences from the control group were recorded at 50 mg/kg bw/day.
Haematology revealed an increase in reticulocyte values and white blood cells males at 1000 mg/kg bw/day; no relevant differences were observed in the remaining groups or females. Clinical chemistry assessment showed an increase in cholesterol and triglyceride levels at 300 and 1000 mg/kg bw/day in males and at 1000 mg/kg bw/day in females. Increases in alkaline phosphatase and alanine aminotransferase were recorded at 1000 mg/kg bw/day in males and females.
Gross necropsy revealed a reddish discoloration of the mesenteric lymph node in both sexes at 1000 mg/kg bw/day. All other gross lesions recorded were considered to be within the normal range of background alterations observed in rats of this strain and age and under the experimental conditions used in this study.
An increase in liver weight was recorded in males at 300 and 1000 mg/kg bw/day and females at 1000 mg/kg bw/day. Moreover, higher kidney weight was recorded in males at 1000 mg/kg bw/day. One male from each test-item-treated group had lower testis weight. No noticeable differences were observed in the remaining animals.
At 1000 mg/kg bw/day, cell hypertrophy in the liver, thyroid and pituitary consistent with liver enzyme induction, as well as, decreased lymphocytes in the mesenteric lymph node and thymus were recorded in both sexes. Increased hyaline droplets in the kidneys were observed in males. The hyaline droplets observed in high dose males are consistent with species specific male kidney nephropathy arising from administration of high oil content doses that may exacerbate the accumulation of alpha2μ-globulin, a unique protein occurring spontaneously in proximal convoluted tubular epithelial cells only in the mature male rat. Thus, the male rat hydrocarbon nephropathy should not be predictive of a normal human renal response. One female at 1000 mg/kg bw/day had vacuolar changes (involving ovary, oviduct and adrenals). At 300 mg/kg bw/day, cell hypertrophy in the liver was recorded in males, but not in females.
Sperm Stage Evaluation showed severe diffuse bilateral tubular degeneration, associated with marked oligospermia or aspermia in the epididymides in males that showed small testes and/or epididymides. No remarkable findings were recorded in the remaining males from high and control groups.
A NOAEL for males of 50 mg/kg bw/day is determined, based on increased liver weight, hepatocyte hypertrophy and a significant increase in serum cholesterol at 300 mg/kg bw/d. A NOAEL for females of 300 mg/kg bw/d is based on reduced weight gain, increased liver weight, hepatocyte hypertrophy and a significant increase in serum cholesterol at the highest dose level of 1000 mg/kg bw/d.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.